Introduction
There is increasing evidence for a cooperative role of tyrosine kinases that promotes cellular proliferation and transcription factors that regulate cellular differentiation in the progression of leukemia. The erythroleukemia induced by Friend virus (FV) occurs in two distinct stages. The initial stage is characterized by a polyclonal expansion of infected erythroblasts. During the late stage of disease, the acquisition of additional genetic changes results in the clonal expansion of fully transformed cells. The first stage of the disease is driven by the interaction of the viral glycoprotein, gp55, with the EpoR and truncated form of the Stk receptor tyrosine kinase, Sf-Stk (Persons et al., 1999) . C57BL/6 mice, which fail to express Sf-Stk, are resistant to Friend disease. However, exogenous expression of Sf-Stk in erythroblasts from C57BL/6 mice, both in vitro and in vivo, restores Epo-independent colony formation and development of erythroleukemia in response to FV infection (Persons et al., 1999; Finkelstein et al., 2002) . Alternatively, although activation of the EpoR by gp55 is not required for the erythroblastosis induced by FV, it is required for the development of polycythemia (Zhang et al., 2006) .
The ability of gp55 to interact with the EpoR could also explain the difference in disease pathogenesis in mice infected with two different variants of FV. FVP induces polycythemia in addition to erythroleukemia, whereas FVA-induced erythroleukemia is associated with anemia. Although both the viral glycoproteins from FVP (gp55 P ) and FVA (gp55 A ) interact with the EpoR (Constantinescu et al., 2003), gp55 A is a weak activator of EpoR signaling, due to alterations in the transmembrane domain (Fang et al., 1998) . Therefore, although activation of Sf-Stk is required for the polyclonal expansion of infected erythroblasts and the subsequent development of leukemia, activation of the EpoR primarily promotes the differentiation of infected cells.
The essential role played by Sf-Stk in the development of Friend disease led us to investigate the downstream signals required for disease pathogenesis. We have demonstrated that the recruitment of a Grb2/Gab2 complex to Sf-Stk in response to viral infection is both necessary and sufficient to promote the development of leukemia (Finkelstein et al., 2002; Teal et al., 2006) . Furthermore, our studies indicated that Gab2, but not the closely related Gab1, can support the Epo-independent growth of FV-infected erythroblasts (Teal et al., 2006) , a hallmark of the early stage of the disease. We identified a Stat3 binding site that is unique to Gab2 and demonstrated that this Stat3 binding motif is required for the Epo-independent growth of infected erythroblasts (Ni et al., 2007) .
Insertional activation of Pu.1 expression in the second stage of Friend disease plays a critical role in maintaining the undifferentiated state of erythroleukemic cells. Pu.1 inhibits GATA-1 function and erythroid differentiation, and RNA interference of Pu.1 induces terminal differentiation and growth arrest of erythroleukemia cells (Papetti and Skoultchi, 2007) . Alternatively, exogenous expression of GATA-1 in erythroleukemia cells reverses tumorigenicity and triggers terminal differentiation of these cells (Choe et al., 2003) . In addition to its critical role in the late stage of Friend disease, previous studies have demonstrated that gp55 leads to upregulation of Pu.1 expression, independent of proviral insertion, suggesting that Pu.1 may also contribute to the early polyclonal expansion of infected erythroblasts (Afrikanova et al., 2002) .
Here, we set out to examine the function of Stat3 in the development of erythroleukemia induced by FV. We demonstrate for the first time that Stat3 is critical for the development of the early stage of Friend disease in vivo, but appears to be dispensable for the expansion of fully transformed cells in the second stage of the disease. Furthermore, studies comparing the response of these mice to FVP vs FVA suggest that Stat3 plays a critical role in regulating the differentiation of infected progenitors in the early stage of Friend disease. Finally, our results clearly identify Pu.1 as a target gene for Stat3 in vivo following infection of mice with FV. The studies described herein support a model whereby the activation of Stat3 in the early stage of erythroleukemia induced by FV inhibits terminal differentiation of the infected erythroblasts, at least in part, through the upregulation of Pu.1 expression, thus promoting the polyclonal expansion of infected erythroblasts. The insertional activation of Pu.1 in the late stage of disease could, ultimately, circumvent the requirement for Stat3 in these cells. ). These mice were infected with FV and spleen weights from these animals were assessed, as a measure of polyclonal erythroblast expansion. Although we observed enlarged spleens in response to FV infection in the control animals, the size of the spleens from Stat3 D/D mice were significantly reduced ( Figure 1a ). Western blot analysis on spleens (Figures 2c-e) . Recent studies have suggested that Stat3 mediates functions that are independent of tyrosine phosphorylation (Yang et al., 2005) , however, mutants of Stat3 that blocked tyrosine phosphorylation (Y750F) or DNA binding (DBD) failed to support the Epo ind growth of Stat3 D/D bone marrow cells in response to FVP (Figure 2c ). Tetramerization, mediated by the N-terminal domain of Stat3, has also been implicated in mediating transcriptional activation by Stat3 (Zhang and Darnell, 2001 Figure 2d ). We have shown previously that Stat3 is recruited to the Sf-Stk signaling complex via a Stat3 docking site on Gab2 (Ni et al., 2007) . To determine whether there is also a differential requirement for Gab2 in the presence or absence of EpoR signaling, we infected wild-type and Gab2À/À mice with FVA or FVP and examined spleen size 2 weeks following infection. As reported previously, we found that Gab2 plays a critical role in the development of splenomegaly following FVP infection (data not shown). However, like Stat3 , Gab2À/À and StkÀ/À mice were infected with FVA, and spleen size was assessed 2 weeks later. Uninfected spleen weights are shown for each genotype. ***Po0.001, **Po0.01, *Po0.05.
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Gab2À/À mice exhibited splenomegaly following infection with FVA ( Figure 3f ). To determine whether susceptibility to FVA, like FVP, also requires Sf-Stk, we infected StkÀ/À mice with FVA, and examined spleen size 2 weeks following infection. Although Stat3
and Gab2À/À mice were susceptible to the early stage of disease induced by FVA, StkÀ/À mice remained resistant to disease induced by FVA (Figure 3f ). D/D mice were significantly higher than those observed in control animals ( Figure 3d ). However, consistent with previous observations that the anemia that develops following infection with FVA is due primarily to hemodilution (Tambourin et al., 1973; Ney and D'Andrea, 2000) , hematocrits dropped in both strains of FVA-infected mice and there was no significant difference in hematocrit between the two strains (data not shown). Taken together, our studies suggest that Stat3 plays a critical role in regulating the proliferation of primary erythroblasts infected with FVP, at least in part, by inhibiting differentiation thus allowing for the expansion infected erythroblasts in the presence of differentiation signals induced by the EpoR. This early regulation of differentiation signals would be dispensable for the development of erythroblastosis induced by FVA, which is a weak activator of EpoR signaling.
Stat3 regulates the expression of Pu.1 in FV-infected cells Expression of Pu.1 in myeloid cells is regulated by Stat3 (Panopoulos et al., 2002) . Therefore, we set out to determine whether FV induces Pu.1 expression in a Stat3-dependent manner. Splenocytes from FVP-infected mice were harvested on days 0 and 14, followed by intracellular staining for Pu.1. The cells were cosorted for M34, a monoclonal antibody which recognizes gp55 from SFFV and gp70 from F-MuLV (Chesebro et al., 1981) . We found that Pu.1 was highly expressed in FVP-infected splenocytes on day 14 postinfection (89%), compared with uninfected control spleens ( Figure 4a, upper panel) .
To determine whether Pu.1 expression is regulated by Stat3 in vivo, we infected mice with FVA, which promotes erythroblastosis in both control and Stat3 Epo ind colony formation in response to FVP requires the expansion of infected erythroblasts, followed by terminal differentiation, induced by EpoR activation. To determine whether Pu.1 plays a role in the Epo ind colony formation induced by FVP in vitro, we transduced primary bone marrow cells from control mice with retroviral vectors expressing wild-type or dominant-negative Pu.1. These cells were infected with FVP, and BFU-E formation in the absence of Epo was assessed. Although exogenous expression of wild-type Pu.1 had no effect on colony formation, expression of the dominant-negative Pu.1 inhibited Epo ind colony formation in response to FV infection (Figure 4d) , indicating that Pu.1 expression may be critical in promoting the expansion of infected cells in vitro, before terminal differentiation. However, expression of exogenous Pu.1 alone in Stat3 D/D bone marrow failed to rescue the response of these cells to FVP infection (Figure 4e ), suggesting that there may be additional targets downstream of Stat3 required for disease development.
To determine whether Stat3 directly interacts with the Pu.1 promoter in infected cells, we analysed an 18 kb genomic sequence upstream of the murine Pu.1 start site. We identified three potential Stat3 binding sites which we termed sites 1, 2 and 3 (Figure 5a ). Site 1 is not conserved in mammals, however, sites 2 and 3 are highly conserved among all species examined (Figure 5b ). Using chromatin immunoprecipitation (ChIP) analysis on splenocytes from control mice infected with FVP or FVA, we observed Stat3 binding to all three sites in the Pu.1 promoter. However, little or no binding was observed in splenocytes from Stat3 D/D animals infected with FVA, which also develop splenomegaly (Figure 5c ). These results are consistent with a role for Stat3 in the direct regulation of Pu.1 expression in vivo.
Stat3 is not required for the expansion of leukemic cells following FV infection
Following the initial stage of Friend disease, in which infected erythroblasts proliferate and differentiate in the spleen in a polyclonal manner, leukemic clones emerge which are capable of forming spleen colonies in FV resistant mice on transplantation. These cells, termed CFU-FV, form blast-like colonies in methylcellulose in the absence of exogenous growth factor stimulation (Mager et al., 1981) . To determine whether Stat3 is required for the generation and/or growth of leukemic cells, we infected Stat3 D/D or control mice with FVA or FVP, isolated splenocytes 4 weeks postinfection, and assessed CFU-FV colony formation. We found that there were reduced numbers of CFU-FV in response to FVP infection (Figure 6a) . However, the size of the CFU-FV colonies derived from Stat3 D/D mice following FVP infection are not significantly different than those that develop from control animals (Figure 6b ). To determine whether these CFU-FV colonies contain Stat3, we performed PCR analysis to genotype individual colonies for deletion of the Stat3 locus. We found that, although some of the colonies contained the wild-type allele of Stat3, others developed from cells in D/D mice was transduced with wild-type or dominant-negative Pu.1 as described above followed by infection with FVP. Cells were plated in methylcellulose and BFU-E numbers were assessed on day 8 following benzidine staining. **Po0.01.
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S Hegde et al which Stat3 was deleted (Figure 6c ). To determine whether these colonies harbor retroviral insertions in the PU.1 locus, we performed PCR analysis of the PU.1 insertion site. Regardless of Stat3 genotype, all of the CFU-FV colonies contained proviral insertions at the PU.1 locus (Figure 6d ). Insertion at this locus was not observed in Epo ind colonies following FVP infection in vitro. These results indicate that Stat3 is not required for the cytokine-independent expansion of leukemic cells that develop in response to FVP infection, and that the requirement for Stat3 may be overcome by genetic alterations that occur at this stage, including insertional activation of PU.1.
To determine whether Gab2 is required for the development or proliferation of leukemic cells in response to FV infection, we compared CFU-FV formation by splenocytes from wild-type or Gab2À/À mice 4 weeks postinfection with FVP. We also observed a significant reduction in CFU-FV development in the absence of Gab2 (Figure 6e ). However, unlike the CFU-FV that arise from Stat3 D/D cells, the colonies that develop from the spleens of Gab2À/À mice are much smaller in size than those derived from wild-type control animals, suggesting that Gab2 may provide signals, in addition to Stat3, that are required for the efficient proliferation of CFU-FV (Figure 6f ). Taken together, these results suggest that, although Gab2 leads to the recruitment and activation of Stat3, which is required for the early stages of disease in response to FVP, Gab2, but not Stat3, plays a critical role in the proliferation of fully transformed leukemic cells.
Discussion
The erythroleukemia induced by FV is a multistep process, characterized by an early stage of erythroblast proliferation and differentiation followed by a late-stage differentiation block and leukemic transformation. The development of leukemia results from the cooperation of two classes of mutations, one conferring a proliferative advantage and one blocking differentiation. In Friend disease, the proliferative signal is a result of the activation of Sf-Stk by the viral glycoprotein, gp55, in the early stage of disease, whereas the block to Stat3 in the progression of Friend erythroleukemia S Hegde et al differentiation is accomplished by insertional activation of the Pu.1 locus in the late stage of the disease. Here, we identify a novel role for Stat3 in the regulation of erythroblast differentiation in the early stage of the disease, thus promoting the expansion of infected erythroblasts induced by Sf-Stk. Furthermore, we have demonstrated, for the first time, a role for Stat3 in the regulation of Pu.1 expression in vivo, suggesting a mechanism by which Stat3 may achieve regulation of differentiation. We propose that Stat3-dependent activation of Pu.1 following infection with FVP, in the absence of proviral activation of Pu.1, tips the balance of signals toward an undifferentiated state in the early progenitor cells, thus promoting the efficient expansion of infected cells before terminal differentiation induced by activation of the EpoR. The result is the development of disease in which infected erythroblasts proliferate, and ultimately differentiate, resulting in the development of Epo ind colonies in vitro and polycythemia in vivo. Previous studies have demonstrated that transgenic expression of Pu.1 in mice results in the multistage development of erythroleukemia (Moreau-Gachelin et al., 1996) . At the onset of disease, these mice become severely anemic, accompanied by a massive expansion of proerythroblasts that are partially blocked in differentiation, followed later by malignant transformation.
-----------------------ctctgacttc--ttTTCTCGGAAgct-cttaagggactgagg Rat aatt-----------------------ccgtggctcc--gtTTCTCGG-Agct-cttgggggattgagg
Interestingly, the majority of tumors isolated from these mice during the late stage of the disease harbored acquired mutations in the Kit receptor (Kosmider et al., 2005) . Conversely, knockdown of Gata-1 results in the development early-onset nonlymphoid leukemias, which are c-Kit-positive. Low-level GATA-1 expression in these animals is sufficient to support survival and proliferation but not differentiation (Shimizu et al., 2004) . These studies support the prediction that two events are required for the development of leukemogenesis, one that promotes proliferation and one that blocks differentiation. Our studies indicate that Stat3 plays a critical role in promoting the block to differentiation in Friend disease, and that the requirement for Stat3 in the late stage of the disease may be negated by the insertional activation of Pu.1 expression by the SFFV provirus.
In conclusion, our data support a model, in which, during the early polyclonal expansion of FVP-infected cells, the viral protein, gp55, leads to the constitutive activation of Sf-Stk which, in turn, recruits a Grb2/ Gab2 complex. The activation of Gab2 by Sf-Stk promotes the Epo ind proliferation and/or survival of infected erythroblasts and, at the same time, inhibits the differentiation of these cells through the activation of Stat3, and the subsequent upregulation of Pu.1 ; Sano et al., 1999) were crossed four generations onto the BALB/c background. The genotype for the Fv2 locus was determined by PCR using the primers 5 0 -GGTGGGTTTAACGGTTAGGG-3 0 and 5 0 -TCTGGGCTCTGCCTCCTTAT-3 0 . These mice were crossed to the IFN-inducible Cre recombinase transgenic mouse line, B6.Cg-Tg(Mx1-cre)1Cgn/J (Kuhn et al., 1995) , also crossed onto the BALB/c background. To delete Stat3, mice were injected with 200 ml of PolyI/PolyC (Cat no. p-1958, Sigma St Louis, MO, USA) in phosphate-buffered saline (PBS) at a concentration of 2 mg/ml intraperitoneally daily for three injections and on alternate days for five injections. The Stat3 locus was genotyped using the primers 5 0 -CCTGAAGAC CAAGTTCATCTGTGTGAC-3 0 , 5 0 -CACACAAGCCATCA AACTCTGGTCTCC-3 0 and 5 0 -GATTTGAGTCAGGGATC CATAACTTCG-3 0 to produce amplified products of the germline (2000 bp), floxed (270 bp) and deleted (75 bp) alleles. The Gab2À/À mice used in this study were described previously (Ni et al., 2007) . All research involving the use of mice was performed in strict accordance with protocols approved by the Institutional Animal Care and Use committee of the Pennsylvania State University.
DNA constructs
Stat3(Y705)F and Stat3(EE/VVV) (DNA-binding domain mutant (DBD)) were obtained from C Horvath (Northwestern University) and MSCV-Stat3, MSCV-Stat3(Y705F) and MSCV-Stat3(DBD) were generated as described previously (Ni et al., 2007) . MSCV-Stat3DN was generated by digesting MSCV-Stat3 with Pst1 and Xba1, resulting in deletion of the first 131 amino acids. MSCV-Stat3W37A/Q66A was generated from MSCV-Stat3 using the primers 5 0 -CGGCAGTTCC TGGCACCTGCGATTGAGAGTCAAGACTGG-3 0 and 5 0 -CCAGTCTTGACTCTCAATCGCAGGTGCCAGGAACT GCCG-3 0 for W37A and the primers 5 0 -CTCTTGGGT GAAATTGACGCGCAATATAGCCGATTCCTG-3 0 and 5 0 -CAGGAATCGGCTATATTGCGCGTCAATTTCACCCAA GAG-3 0 for Q66A as described previously (Zhang and Darnell, 2001) . Serine 727 was mutated to alanine using the primers 5 0 -AGCCAAGGAGACTGCCGGATCTGA3 0 and 5 0 -TCAGA TCCGGCAGTCTCCTTGGCT-3 0 . Lysine 685 was mutated to arginine using the primers 5 0 -CGGAAGCGAGTGCAG CAGGATCTA-3 0 and 5 0 -TAGATCCTGCTGCACTCGCT TCCG-3 0 . To generate gp55 A , a M390I mutation was introduced into gp55 P using primers 5 0 -CGTTGATATCCGCCATCATCG GGTCTCTCATTATACTCC-3 0 and 5 0 -GGAGTATAATG AGAGACCCGATGATGGCGGATATCAACG-3 0 . A double deletion of L399 and L400 was introduced using primers 5 0 -GTCTCTCATTATACTCCTACTCATTCTGCTTATTTGG ACCCTG-3 0 and 5 0 -CAGGGTCCAAATAAGCAGAATGA GTAGGAGTATAATGAGAGAC-3 0 . All point mutations and deletions were generated using the Stratagene (La Jolla, CA, USA) QuikChange mutagenesis kit.
Generation of viral supernatants 293T cells were grown in Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal calf serum, penicillin-streptomycin and L-glutamine. Cells were transiently transfected with 1-2 mg pEco and 2.5 mg murine stem cell virus (MSCV) using the Trans IT-293 transfection reagent (Mirus corporation, Madison, WI, USA) at 37 1C for 48-72 h before harvest of the viral supernatant.
In vitro bone marrow infections and colony assays Primary bone marrow cells were infected with viral supernatants from the transient transfections for 20 h. For Epoindependent colony assays, the bone marrow cells were incubated with supernatants from cells expressing FVP or DMEM on ice for 1 h. The cells were then added to Methocult Medium M3234 (Stemcell Technologies, Vancouver, BC, USA), along with 2.5 ng interleukin (IL)-3 (Peprotech, Rocky Hill, NJ, USA), in triplicate with or without 1 U/ml Epo (R&D Systems, Minneapolis, MN, USA). Cultures were incubated for 8 days in 5% CO2 at 37 1C. Erythroid colonies were visualized by acid-benzidine staining. For the CFU-FV assay, mice were injected with FVP and 4 weeks later, splenoctyes were isolated and plated on Methocult M3231 (Stemcell Technologies). CFU-FV colonies were scored after 2 weeks. To detect the presence of the provirus in the Pu.1 locus we utilized a primer in the viral LTR, 5 0 -CACTAGAATACGA GCCACGATAAAT-3 0 and a primer in the Pu.1 gene, 5 0 -CT TTCACTTGTGTAGTTGAAGATGG-3 0 . DNA from individual CFU-FV were subjected to 37 cycles of PCR of 1 min at 94C, 30 s at 60 1C and 3 min at 68 1C, in a final volume of 50 ml, using Takara Extaq (Code no. RR001).
Antibodies and western blot analysis Anti-Stat3 was purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA; Cat no. SC-482). Anti-phospho-Stat3 (Cat no. 9131) and anti-myc were purchased from Cell Signaling (Danvers, MA, USA). Rabbit anti-b-actin was purchased from Sigma. Protein G magnetic beads were purchased from New England BioLabs. Cells were lysed in lysis buffer (1% NP-40, 150 mM Nac1, 1 mM EDTA, 0.25% deoxycholate, 2 mM Na 3 VO 4 , 10 mM NaF, 2 mM phenylmethylsulfonyl fluoride). After 15 min of centrifugation, the cleared lysates were immunoprecipitated and/or resolved by reduced SDS-polyacrylamide gel electrophoresis, the blots were incubated with the indicated antibodies and the bands were visualized with ECL (Amersham, Piscataway, NJ, USA).
Flow Cytometry
Mice were injected with FVP retroorbitally. Splenocytes were blocked with Fc block (BD Pharmingen) and stained with the M34 antibody (Chesebro et al., 1981) conjugated with FITC and Pu.1 antibody conjugated with PE (Santa Cruz Biotechnology) for analysis by flow cytometry. 
RT-PCR
Quantitative RT-PCR was performed for Pu.1. using superscript II RNase H reverse transcriptase (Invitrogen Life Technologies), the 7300 Real-time PCR system (Applied Biosystems) and the Taqman genexpression assay for Pu.1 (Mm01719550) and GapDH (Mm99999915g1) from Applied Biosystems.
Chromatin immunoprecipitation
Mice were injected with FVP or FVA and splenocytes were isolated on day 10. Chromatin was prepared using the EZZyme chromatin kit. The samples were immunoprecipitated with anti-Stat3 (Cell Signaling; Cat no. 9132) and DNA was isolated using the Magna ChIP kit (Upstate Biotechnology, Lake Placid, NY, USA). The Primers used for PCR were: Site 1, 5 0 -ACTTTAAAGCCCAGCACTCG-3 0 and 5 0 -ATCCATC CATCCATGCATCT-3 0 ; Site 2, 5 0 -CCAGGAACCGGAATA GAACA-3 0 and 5 0 -CATGCCAACCAGAAGACTCA-3 0 ; Site 3, 5 0 -GAGAGCAGAGGGCTCAGAGA-3 0 and 5 0 -AGTCCC GTCTCCAGAACTCA-3 0 . Nonspecific DNA in the immunoprecipitates was analysed using 5X excess template and the primers in the IL-2 gene: 5 0 -CTAGGCCACAGAATTGAAAGATC T-3 0 and 5 0 -GTAGGTGGAAATTCTAGCATCATCC-3 0 .
Intracellular staining for Pu.1 Cells were fixed for 40 min at room temperature with 200 ml of 1 Â formaldehyde buffer (2.7 ml 37% formaldehyde solution in 1 Â PBS). The cells were centrifuged and the fixation solution was decanted. The cells were permeabilized with 200 ml 70% EtOH and incubated for 50 min at À20 1C. EtOH was decanted, the cells were washed with PBS and incubated with anti-Pu.1 antibody (Santa Cruz; Cat no. SC-352) for 45 min on ice. Cells were washed with PBS and incubated with anti-rabbit Alexa 660 (Invitrogen; A21074) for 45 min on ice. Cells were washed and Pu.1 staining was detected by flow cytometry.
Statistics
Statistical evaluation was performed using the Student's t-test. Po0.05 was considered statistically significant.
